• Je něco špatně v tomto záznamu ?

Building a network of ADPKD reference centres across Europe: the EuroCYST initiative

K. Petzold, RT. Gansevoort, AC. Ong, O. Devuyst, L. Rotar, KU. Eckardt, A. Köttgen, Y. Pirson, G. Remuzzi, R. Sandford, V. Tesar, T. Ecder, D. Chaveau, R. Torra, K. Budde, Y. Le Meur, RP. Wüthrich, AL. Serra,

. 2014 ; 29 Suppl 4 (-) : iv26-32.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15007943

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic inherited kidney disease, affecting an estimated 600 000 individuals in Europe. The disease is characterized by age-dependent development of a multiple cysts in the kidneys, ultimately leading to end-stage renal failure and the need of renal replacement therapy in the majority of patients, typically by the fifth or sixth decade of life. The variable disease course, even within the same family, remains largely unexplained. Similarly, assessing disease severity and prognosis in an individual with ADPKD remains difficult. Epidemiological studies are limited due to the fragmentation of ADPKD research in Europe. METHODS: The EuroCYST initiative aims: (i) to harmonize and develop common standards for ADPKD research by starting a collaborative effort to build a network of ADPKD reference centres across Europe and (ii) to establish a multicentric observational cohort of ADPKD patients. This cohort will be used to study factors influencing the rate of disease progression, disease modifiers, disease stage-specific morbidity and mortality, health economic issues and to identify predictive disease progression markers. Overall, 1100 patients will be enrolled in 14 study sites across Europe. Patients will be prospectively followed for at least 3 years. Eligible patients will not have participated in a pharmaceutical clinical trial 1 year before enrollment, have clinically proven ADPKD, an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m(2) and above, and be able to provide written informed consent. The baseline visit will include a physical examination and collection of blood, urine and DNA for biomarker and genetic studies. In addition, all participants will be asked to complete questionnaires detailing self-reported health status, quality of life, socioeconomic status, health-care use and reproductive planning. All subjects will undergo annual follow-up. A magnetic resonance imaging (MRI) scan will be carried out at baseline, and patients are encouraged to undergo a second MRI at 3-year follow-up for qualitative and quantitative kidney and liver assessments. CONCLUSIONS: The ADPKD reference centre network across Europe and the observational cohort study will enable European ADPKD researchers to gain insights into the natural history, heterogeneity and associated complications of the disease as well as how it affects the lives of patients across Europe.

Academic Department of Medical Genetics University of Cambridge Cambridge UK

Department of Internal Medicine 4 University Medical Center Freiburg Freiburg Germany

Department of Nephrology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Nephrology and Hypertension Friedrich Alexander Universität Erlangen Nürnberg Erlangen Germany

Department of Nephrology Centre Hospitalier Universitaire de Brest Brest France

Department of Nephrology Charité Campus Mitte Charité Universitätsmedizin Berlin Berlin Germany

Department of Nephrology Cliniques Universitaires Saint Luc Brussel Belgium

Department of Nephrology Istanbul School of Medicine Istanbul Turkey

Department of Nephrology University Medical Center Groningen University of Groningen Groningen The Netherlands

Division of Nephrology University Hospital Zurich Zurich Switzerland

Inherited Kidney Diseases Nephrology Department Fundació Puigvert Instituto de Investigaciones Biomédicas Sant Pau Universitat Autònoma de Barcelona REDinREN Instituto de Investigación Carlos 3 Barcelona Spain

Institute of Physiology and Zurich Center for Integrative Human Physiology University of Zurich Zurich Switzerland

Institute of Physiology and Zurich Center for Integrative Human Physiology University of Zurich Zurich Switzerland Division of Nephrology University Hospital Zurich Zurich Switzerland

IRCCS Istituto di Ricerche Farmacologiche Mario Negri Centro Anna Maria Astori Bergamo Italy and Unit of Nephrology Dialysis and Transplantation A O Papa Giovanni XXIII Bergamo Italy

Kidney Genetics Group Academic Nephrology Unit Department of Infection and Immunity University of Sheffield Medical School Sheffield UK

Service de nephrologie et immunologie clinique centre de reference des maladies renales rares CHU de Toulouse universite' de Toulouse 3 hopital Rangueil

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15007943
003      
CZ-PrNML
005      
20150331105958.0
007      
ta
008      
150306s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ndt/gfu091 $2 doi
035    __
$a (PubMed)25165183
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Petzold, Katja $u Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
245    10
$a Building a network of ADPKD reference centres across Europe: the EuroCYST initiative / $c K. Petzold, RT. Gansevoort, AC. Ong, O. Devuyst, L. Rotar, KU. Eckardt, A. Köttgen, Y. Pirson, G. Remuzzi, R. Sandford, V. Tesar, T. Ecder, D. Chaveau, R. Torra, K. Budde, Y. Le Meur, RP. Wüthrich, AL. Serra,
520    9_
$a BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic inherited kidney disease, affecting an estimated 600 000 individuals in Europe. The disease is characterized by age-dependent development of a multiple cysts in the kidneys, ultimately leading to end-stage renal failure and the need of renal replacement therapy in the majority of patients, typically by the fifth or sixth decade of life. The variable disease course, even within the same family, remains largely unexplained. Similarly, assessing disease severity and prognosis in an individual with ADPKD remains difficult. Epidemiological studies are limited due to the fragmentation of ADPKD research in Europe. METHODS: The EuroCYST initiative aims: (i) to harmonize and develop common standards for ADPKD research by starting a collaborative effort to build a network of ADPKD reference centres across Europe and (ii) to establish a multicentric observational cohort of ADPKD patients. This cohort will be used to study factors influencing the rate of disease progression, disease modifiers, disease stage-specific morbidity and mortality, health economic issues and to identify predictive disease progression markers. Overall, 1100 patients will be enrolled in 14 study sites across Europe. Patients will be prospectively followed for at least 3 years. Eligible patients will not have participated in a pharmaceutical clinical trial 1 year before enrollment, have clinically proven ADPKD, an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73 m(2) and above, and be able to provide written informed consent. The baseline visit will include a physical examination and collection of blood, urine and DNA for biomarker and genetic studies. In addition, all participants will be asked to complete questionnaires detailing self-reported health status, quality of life, socioeconomic status, health-care use and reproductive planning. All subjects will undergo annual follow-up. A magnetic resonance imaging (MRI) scan will be carried out at baseline, and patients are encouraged to undergo a second MRI at 3-year follow-up for qualitative and quantitative kidney and liver assessments. CONCLUSIONS: The ADPKD reference centre network across Europe and the observational cohort study will enable European ADPKD researchers to gain insights into the natural history, heterogeneity and associated complications of the disease as well as how it affects the lives of patients across Europe.
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    12
$a zdravotnické služby $7 D006296
650    _2
$a zdravotní stav $7 D006304
650    _2
$a lidé $7 D006801
650    _2
$a longitudinální studie $7 D008137
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a polycystické ledviny autozomálně dominantní $x patofyziologie $x terapie $7 D016891
650    _2
$a prognóza $7 D011379
650    _2
$a průzkumy a dotazníky $7 D011795
650    12
$a konziliární vyšetření a konzultace $7 D012017
650    12
$a výzkumný projekt $7 D012107
650    _2
$a standardní péče $x organizace a řízení $7 D059039
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Gansevoort, Ron T $u Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
700    1_
$a Ong, Albert C M $u Kidney Genetics Group, Academic Nephrology Unit, Department of Infection and Immunity, University of Sheffield Medical School, Sheffield, UK.
700    1_
$a Devuyst, Olivier $u Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
700    1_
$a Rotar, Laura $u Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
700    1_
$a Eckardt, Kai-Uwe $u Department of Nephrology and Hypertension, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
700    1_
$a Köttgen, Anna $u Department of Internal Medicine IV, University Medical Center Freiburg, Freiburg, Germany.
700    1_
$a Pirson, Yves $u Department of Nephrology, Cliniques Universitaires Saint-Luc, Brussel, Belgium.
700    1_
$a Remuzzi, Giuseppe $u IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Bergamo, Italy and Unit of Nephrology, Dialysis and Transplantation, A.O. Papa Giovanni XXIII, Bergamo, Italy.
700    1_
$a Sandford, Richard $u Academic Department of Medical Genetics, University of Cambridge, Cambridge, UK.
700    1_
$a Tesar, Vladimir $u Department of Nephrology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Ecder, Tevfik $u Department of Nephrology, Istanbul School of Medicine, Istanbul, Turkey.
700    1_
$a Chaveau, Dominique $u Service de nephrologie et immunologie clinique, centre de reference des maladies renales rares (SORARE), CHU de Toulouse, universite' de Toulouse III, hopital Rangueil.
700    1_
$a Torra, Roser $u Inherited Kidney Diseases, Nephrology Department, Fundació Puigvert, Instituto de Investigaciones Biomédicas Sant Pau (IIB-Sant Pau), Universitat Autònoma de Barcelona, REDinREN, Instituto de Investigación Carlos III, Barcelona, Spain.
700    1_
$a Budde, Klemens $u Department of Nephrology, Charité Campus Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany.
700    1_
$a Le Meur, Yannick $u Department of Nephrology, Centre Hospitalier Universitaire de Brest, Brest, France.
700    1_
$a Wüthrich, Rudolf P $u Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
700    1_
$a Serra, Andreas L $u Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
773    0_
$w MED00010288 $t Nephrology, dialysis, transplantation official publication of the European Dialysis and Transplant Association - European Renal Association $x 1460-2385 $g Roč. 29 Suppl 4, č. - (2014), s. iv26-32
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25165183 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20150331110228 $b ABA008
999    __
$a ok $b bmc $g 1065216 $s 890743
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 29 Suppl 4 $c - $d iv26-32 $i 1460-2385 $m Nephrology, dialysis, transplantation $n Nephrol Dial Transplant $x MED00010288
LZP    __
$a Pubmed-20150306

Najít záznam

Citační ukazatele

Možnosti archivace